Litigation Details for JANSSEN PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC. (D.N.J. 2008)

JANSSEN PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC. (D.N.J. 2008)

Docket		Date Filed	2008-10-16
Court	District Court, D. New Jersey	Date Terminated	2012-09-11
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	6,214,815
Attorneys	CARISSA L. RODRIGUE
Firms	McCarter and English, LLP
Link to Docket	External link to docket

Details for JANSSEN PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC. (D.N.J. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-10-16				External link to document

Litigation summary and analysis for: JANSSEN PHARMACEUTICALS, INC. v. WATSON LABORATORIES, INC. (D.N.J. 2008)

Last updated: June 17, 2026

Janssen v. Watson Laboratories (2:08-cv-05103): litigation summary, claims at issue, and what it meant for generic launch risk

Janssen Pharmaceuticals, Inc. v. Watson Laboratories, Inc., case 2:08-cv-05103 is a federal patent infringement dispute in which Janssen asserted patent rights against Watson in connection with a generic launch pathway. The litigation’s practical impact is assessed through the typical post-filing outcomes that drive Orange Book exclusivity and Paragraph IV leverage: (1) whether patents-in-suit were narrowed, (2) whether Watson obtained a non-infringement or invalidity ruling, (3) whether a settlement triggered an “at-risk” or delayed generic entry date, and (4) how the outcome aligned with FDA approval timing.

What patents were asserted in Janssen v. Watson 2:08-cv-05103?

Direct answer: The case caption alone does not identify the specific active ingredient, product, or patents asserted. A litigation summary that is decision-grade requires the patents-in-suit (listed in the complaint and/or claim chart), the asserted claims, and the procedural posture (motions, trial dates, and final judgment).

Because the patent numbers, asserted claims, and judgment text are not provided in the input, no complete, accurate litigation summary can be produced.

What drug and formulation were at issue?

A Janssen vs. Watson filing in the late 2000s usually maps to an FDA ANDA or section 505(b)(2) dispute, with claims directed to:

• drug composition or specific chemical compounds
• polymorph/solid-state forms
• formulation/excipients and manufacturing methods
• method-of-use or dosing regimens

But the drug name and dosage form are not provided here, so the asserted scope cannot be tied to specific IP.

What claim elements were disputed?

Decision-grade patent litigation analysis depends on what Watson attacked:

• non-infringement theory (no literal infringement and/or no equivalents)
• invalidity grounds (anticipation, obviousness, written description, enablement, indefiniteness)
• inequitable conduct or priority date disputes

No claim-level disputes are provided.

What was the procedural timeline for 2:08-cv-05103?

Direct answer: The input does not include the docket’s key dates, so the procedural timeline cannot be stated accurately (complaint filing, answer, Markman, summary judgment, trial, final judgment, and any appeals).

What were the key milestones that drive exclusivity timing?

In Hatch-Waxman cases, key milestones that control “when exclusivity ends” and “when generics can launch” include:

• initial complaint and service date
• any preliminary injunction request and ruling
• Markman claim construction order dates
• summary judgment outcomes
• appellate decisions affecting enforceability
• settlement agreement effective date (if applicable)

None of these dates are included in the input.

Did Janssen win, and did Watson launch ‘at risk’ after 2:08-cv-05103?

Direct answer: The input does not include the disposition of the case (dismissal, consent judgment, final judgment after trial, or settlement). Without the docket outcome, it is not possible to determine:

• whether the asserted patents were found infringed
• whether the patents were invalidated
• whether the case was mooted by settlement
• whether FDA approval resulted in “at risk” launch and when

What does the disposition mean for generic entry risk?

If Janssen won on infringement and no invalidity held, the risk profile is typically higher: the generic launch date is pushed later, often aligned to the latest expiring asserted patent or any non-expired exclusivity. If Watson prevailed (invalidity or non-infringement), risk drops and FDA approval can translate into earlier entry.

The case outcome is not provided, so no accurate risk conclusion can be drawn.

What did the litigation cover: composition, formulation, method-of-use, or manufacturing?

Direct answer: The topic scope cannot be identified from the case caption alone.

Typical Janssen v. Watson patent themes in this era

Depending on the therapeutic area, common Janssen-era patent estates attacked by generic filers include:

• extended-release formulations (matrix, beads, film-coating systems)
• solubility and bioavailability improvements via formulation components
• manufacturing parameters tied to particle size, dissolution profile, or solid-state form
• polymorph control and process claims
• method-of-use dosing regimens with specific patient populations

No product-specific patent categories are provided for 2:08-cv-05103.

How does 2:08-cv-05103 affect FDA ANDA timing and Orange Book status?

Direct answer: Without the drug name and the specific patents asserted, Orange Book mapping cannot be performed. Orange Book analysis requires:

• the Orange Book NDA/ANDA listing
• the listed patents and their expiration dates
• the “patent-by-patent” status (expiration, litigation stay, carve-out, or delistings)
• whether the case triggered the 30-month stay under 21 U.S.C. § 355(j)(5)(B)

No Orange Book entry identifiers are provided in the input.

Were there Paragraph IV challenges in Janssen v. Watson 2:08-cv-05103?

Direct answer: The presence of a Hatch-Waxman Paragraph IV dispute cannot be confirmed from the input alone.

Settlement patterns that would determine market timing

When Paragraph IV is involved, the settlement often includes:

• agreed entry date
• license terms
• covenant not to sue prior to that date
• restrictions on design-arounds
• labeling limitations

No settlement terms or date are provided.

Which companies besides Watson were involved, and what is the competitive landscape?

Direct answer: The input only names Janssen and Watson. It does not provide:

• whether other defendants were joined
• whether Watson Labs is the applicant entity vs. a marketing labeler
• whether another generic challenger was consolidated or co-defendant
• whether a later “design-around” competitor entered first

No further party information is provided.

How strong was Janssen’s patent estate in 2:08-cv-05103?

Direct answer: Patent strength requires at least one of:

• list of asserted patents and claim scope
• court rulings on claim construction and dispositive motions
• final judgment invalidity/infringement outcomes
• appellate history

None of these are present in the input.

What did claim construction do to the case?

In most litigations, Markman construction changes the infringement map and can:

• narrow the asserted scope
• render certain design features non-infringing
• support a validity attack if prior art matches the construed limitation

No claim construction outcomes are provided.

Key facts table: what can and cannot be concluded from the provided input

Litigation field	Value from input	Litigation-grade assessment
Case number	2:08-cv-05103	Identifies the docket, not the substantive issues
Parties	Janssen Pharmaceuticals, Inc. v. Watson Laboratories, Inc.	Establishes plaintiff/defendant but not product/patents
Court level	Federal case (implied)	Venue/jurisdiction not provided
Patents asserted	Not provided	Cannot summarize claims at issue
Procedural milestones	Not provided	Cannot build timeline
Disposition	Not provided	Cannot determine infringement/invalidity result
Settlement	Not provided	Cannot state entry date impact
FDA/Orange Book linkage	Not provided	Cannot map to exclusivity/30-month stay

Key Takeaways

• The provided input identifies the case caption and docket number but does not include the patent numbers, asserted claims, procedural history, or final disposition.
• A litigation summary that supports licensing, litigation strategy, or investment decisions requires those specifics; without them, no complete and accurate analysis can be produced.
• No Orange Book exclusivity conclusions, Paragraph IV confirmation, or generic launch timing can be stated from the input alone.

FAQs

1. What is typically covered in Janssen vs. Watson Hatch-Waxman patent cases?
   Usually composition/formulation/method-of-use claims tied to an ANDA product profile and FDA approval timing, depending on the patents asserted.

2. How do court rulings in patent cases translate into generic entry timing?
   Dispositive rulings (invalidity/non-infringement) or settlements can remove or reduce barriers to an FDA approval-to-launch pathway.

3. What information is needed to map a litigation to Orange Book patents?
   The specific patents-in-suit and the NDA/ANDA product listing that carries those patents.

4. How do Markman claim constructions affect infringement outcomes?
   Constructions can narrow claim scope and change whether the accused product meets each limitation.

5. What settlement terms most affect market impact in these disputes?
   Entry dates, license covenants, design-around constraints, and any restrictions on labeling or launch sequencing.

References

(No sources are cited because the input does not include docket documents, opinions, complaint text, patent numbers, or FDA/Orange Book identifiers.)